HSBC reiterates 'hold' on Astrazeneca
17th Jun 2016 10:59
(ShareCast News) - HSBC reiterated a 'hold' rating on Astrazeneca after the US consumer watchdog increased its drug safety warning of the risk of acute kidney failure for the SGLT-2 inhibitors Farxiga and Invokana. The US Food and Drug Administration (FDA) has revised the warnings in the labels of t
Read moreThursday broker round-up
9th Jun 2016 16:34
(ShareCast News) - Fevertree Drinks: Berenberg upgrades to buy with a target price of 810p. AO World: JP Morgan keeps at neutral with a 200p target. WH Smith: JP Morgan stays at overweight with a target price of 1850p. Lancashire Holdings: UBS keeps at neutral with a target of 610p. Admiral Group
Read moreAstraZeneca in $770m deal with Aspen Group
9th Jun 2016 07:36
(ShareCast News) - AstraZeneca said it has entered a $770m commercialisation deal with Aspen Global Incorporated (AGI), part of the the US Aspen Group, for rights to its global anaesthetics portfolio outside the US. Under the terms of the agreement, AGI will acquire the commercialisation rights, out
Read moreAstraZeneca completes Zurampic deal with Ironwood
3rd Jun 2016 07:52
(ShareCast News) - Drugmaker AstraZeneca continued its charge of licensing its Zurampic (lesinurad) drug on Friday, with the company announcing it has completed its licensing agreement with Ironwood Pharmaceuticals for the exclusive United States rights to the drug. The FTSE 100 firm said the agreem
Read moreAstraZeneca signs major deal with Grunenthal over Zurampic
2nd Jun 2016 07:08
(ShareCast News) - Pharmaceutical and biologics company AstraZeneca announced on Thursday that it has entered into a licensing agreement with Grünenthal GmbH for the exclusive rights to Zurampic (lesinurad) in Europe and Latin America. The FTSE 100 firm received approval from the European Medicines
Read moreSunday newspaper round-up: AstraZeneca, oil IPOs, M&S, Exova, Tesco
29th May 2016 16:22
(ShareCast News) - AstraZeneca, the UK's second-biggest drug developer, will this week outline its next big hope in the battle against cancer by unveiling new data on a class of treatments, known as DNA damage response (DDR) medicines, at a conference in Chicago. The drugs work by stopping cancerous
Read moreAstraZeneca gets positive breast cancer trial results; potassium drug suffers setback
27th May 2016 07:32
(ShareCast News) - Phamaceuticals giant AstraZeneca announced positive results for its Faslodex drug for the treatment of metastatic breast cancer, but also said US regulators will not currently approve its new drug for high potassium levels because of a manufacturing issue. The company said on Frid
Read moreLondon pre-open: G7 warns of Brexit risks
27th May 2016 07:29
(ShareCast News) - Stocks are set for a slightly lower open as traders tread cautiously ahead of a speech by Fed chair Janet Yellen towards the close of trading in London and ahead of the release of key economic indicators Stateside. The fact that investors are heading into a long weekend on both si
Read moreAstraZeneca's Lynparza fails in combination trial
18th May 2016 07:37
(ShareCast News) - AstraZeneca said on Wednesday that its trial of ovarian cancer drug Lynparza in combination with chemotherapy, compared with paclitaxel hemotherapy alone, did not meet the primary endpoint of overall survival in advanced gastric cancer patients. The drugmaker said while there was
Read moreAstraZeneca asthma drug 'well tolerated' in trials
17th May 2016 07:41
(ShareCast News) - AstraZeneca said Tuesday its potential new asthma treatment benralizumab had shown positive results in a phase III trial. In a statement, the company said benralizumab had been "was well tolerated and achieved the primary endpoint in two pivotal Phase III registrational trials dem
Read moreSunday newspaper round-up: RBS, Shell, Cobham, BT, banks
15th May 2016 17:01
(ShareCast News) - Royal Bank of Scotland is examining a range of radical options to help speed the long-delayed separation and flotation of its Williams & Glyn subsidiary, including a potential divestment of its NatWest brand. Banking sources have indicated to the Sunday Telegraph that RBS and its
Read moreAstraZeneca's selumetinib receives Orphan Drug Designation
12th May 2016 08:01
(ShareCast News) - AstraZeneca was celebrating on Thursday, after the US Food and Drug Administration granted its investigational MEK ½ inhibitor, selumetinib, 'Orphan Drug Designation' for adjuvant treatment of patients with stage III or IV differentiated thyroid cancer. The FTSE 100 company said d
Read moreLondon pre-open: All eyes on BoE's Carney and Vlieghe
12th May 2016 07:24
(ShareCast News) - A cautious tone is expected to prevail at the start of trading, with traders sitting on their hands of the results of today's Monetary Policy Committee meeting, minutes and Inflation Report. Against that backdrop, the Footsie is being called to start the session 27 points beneath
Read moreAstraZeneca, Shell plotting debt sales ahead of ECB corporate QE-programme
9th May 2016 15:31
(ShareCast News) - AstraZeneca was marketing €2.2bn of debt in a three-part of deal, according to people familiar with the deal cited by Bloomberg. Airbus Group and Royal Dutch Shell were also marketing their own bonds, the same people said, with US outfit Bunge and Spanish insurer Mapfre having als
Read moreLondon pre-open: Stocks seen higher on upbeat US cues
3rd May 2016 07:28
(ShareCast News) - London stocks were expected to open in the black on Tuesday, taking their cue from a positive session in the US as traders return to their desks following the long bank holiday weekend. The FTSE 100 was seen opening 28 points higher than Friday's close at 6,270. On the data front
Read more